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Abstract
Background: The endogenous secretory receptor for advanced glycation end products (esRAGE) is a soluble
isoform produced by alternative splicing of the RAGE gene. The isoform has anti-inflammatory properties due to its
inhibition of the RAGE/ligand interaction and is reduced in the lung tissue of patients with idiopathic pulmonary
fibrosis (IPF). This study aimed to investigate the association of esRAGE serum and bronchoalveolar lavage fluid
(BALF) levels with progression of IPF.
Methods: This study included 79 IPF patients and 90 healthy controls. IPF and control serum esRAGE levels were
compared, and the correlation between serum and BALF esRAGE levels was analyzed in 57 IPF patient samples. We
also investigated the relationship of esRAGE serum and BALF levels with prognoses and lung function parameters
in patients with IPF.
Results: Serum esRAGE levels in IPF patients were significantly lower than those in healthy controls (162.0 ± 102.4
ng/ml and 200.7 ± 107.3 ng/ml, p = 0.009), although the baseline characteristics of age and smoking history were
not matched. Serum levels of esRAGE were correlated with BALF esRAGE levels (rs = 0.317). The BALF esRAGE levels
were also correlated with diffusion capacity for carbon monoxide (rs = 0.406). A Kaplan-Meier curve analysis and
univariate/multivariate Cox hazard proportion analysis revealed that lower levels of esRAGE in blood and BALF were
significantly associated with poorer prognoses in patients with IPF.
Conclusions: Decreased esRAGE levels in BALF and blood were associated with poor prognoses in patients with
IPF. These results suggest that esRAGE could be related to the pathophysiology of IPF and serum esRAGE could be
a potential prognostic marker of IPF.
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Background
The receptor for advanced glycation end-product (RAGE)
is a transmembrane receptor that can bind numerous li-
gands, and the RAGE/ligand interaction results in cellular
activation and gene transcription [1, 2]. Although the ex-
pression of RAGE is at low levels in the majority of nor-
mal tissues, it is abundantly expressed in the normal lung,
especially in type 1 pneumocytes [3–5]. Idiopathic pul-
monary fibrosis (IPF) is a progressive, fibrotic lung disease
with poor prognosis, characterized by recurrent alveolar
epithelial injury followed by aberrant tissue repair and ex-
cessive matrix deposition [6, 7]. Previous studies have
shown that RAGE expression in lung tissue is reduced in
IPF when compared with controls, and functional poly-
morphism of the RAGE gene is associated with risk of IPF
[8–11]. Additionally, in RAGE knockout mice, pulmonary
fibrosis is caused by aging and may be further aggravated
by exposure to asbestos [12]; therefore, RAGE may play a
homeostatic role in the lungs. These observations indicate
that decreased expression of RAGE in the lungs is associ-
ated with the development and severity of IPF.
Alternative splicing of RAGE gene leads to the for-
mation of endogenous secretory RAGE (esRAGE),
which lacks the transmembrane domain but has an
extracellular ligand-binding domain; it has anti-
inflammatory properties and acts as a decoy neutraliz-
ing RAGE-ligands [13–17]. Interestingly, proteomic
analysis demonstrated that, compared to control sub-
jects, the expression of esRAGE was reduced in the
lung tissue of patients with IPF and not in chronic
obstructive pulmonary disease (COPD) [9]. This sug-
gests that esRAGE may be related to the pathophysi-
ology of IPF. On the other hand, there have been no
studies investigating the association between circula-
tory esRAGE and the disease severity and prognosis
of IPF.
This study aimed to investigate whether esRAGE
concentrations in blood and bronchoalveolar lavage
fluid (BALF) are associated with the prognoses of IPF,
and to explore esRAGE regulatory mechanisms by fo-
cusing on RAGE gene polymorphisms. First, we mea-
sured esRAGE levels in the serum and BALF and
evaluated their correlation. Second, we analyzed the
association of esRAGE levels in the serum and BALF
with pulmonary function parameters and prognosis in
patients with IPF. Additionally, the correlation be-
tween esRAGE levels and differential cell counts in
the BALF was investigated, because inflammatory cells
in the lung are reported to express RAGE [18, 19].
Finally, an exploratory analysis investigated the associ-
ation of esRAGE concentrations with two RAGE gene
polymorphisms: rs1800624 and rs1800625, which




A total of 79 IPF patients and 90 healthy control sub-
jects were included in the present study. The patients
first visited the Department of Respiratory Medicine in
Hiroshima University Hospital (Hiroshima, Japan) from
2003 to 2015, and the diagnosis of IPF was confirmed on
retrospective review based on the ATS/ERS criteria [7].
As a result, sixty-six IPF patients were diagnosed with
usual interstitial pneumonia (UIP) pattern on high-
resolution computed tomography (HRCT), and 13 IPF
patients were diagnosed with possible UIP pattern on
HRCT and histological UIP pattern in surgical lung bi-
opsies. Additionally, BALF samples were obtained during
bronchoscopy from 57 of the 79 patients with IPF. This
study was approved by the Ethics Committee of Hiro-
shima University Hospital (IRB33 approved in 2001 and
M326 approved in 2004), and all participants provided
written informed consent.
Serum and BALF measurements and pulmonary function
tests
Serum and BALF samples were collected at diagnosis
and stored at − 80 °C. BALF was obtained under local
anesthesia by introducing 50mL of saline into the lung
and promptly drawing it out again via a bronchoscope
[21]. These procedures were repeated three times, and,
in total, 150 mL of saline was introduced. The target re-
gion (determined by the HRCT results) was either the
middle lobe or the lingular segment, depending on
which was most severely affected. All of the retrieved sa-
line was mixed and centrifuged, and the supernatant was
collected. esRAGE levels were measured with a commer-
cially available enzyme-linked immunosorbent assay
(ELISA) kits, according to the manufacturer’s instruc-
tions (esRAGE ELISA kit, B-Bridge International, Sunny-
vale, CA, USA). The esRAGE levels in the serum and
BALF were fully within the measurable range; this was
confirmed by duplicate analysis.
Pulmonary function variables were measured using
spirometry (Chestac-55 V and Chestac-8800, CHEST,
Tokyo Japan) in accordance with the American Thoracic
Society and the European Respiratory Society recom-
mendations [22].
DNA preparation and genotyping
Peripheral whole venous blood samples were gathered
from all participants and stored at − 80°C. Genomic
DNA was extracted with the phenol-chloroform extrac-
tion and ethanol precipitation methods, as previously de-
scribed [23, 24]. The RAGE gene polymorphisms were
genotyped successfully for all patients and healthy con-
trols. The genotypes were determined using a commer-
cially available polymerase chain reaction (PCR) assay.
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Each sample contained 10 μl of the PCR mixture, which
in turn contained 0.25 μl of TaqMan SNP Genotyping
Assay (C_3293837_1, C_8848033_1, C_2412456_10),
1.0 μl of genomic DNA (2.0 g/mL), 3.75 μl of double dis-
tilled water, and 5.0 μl of TaqMan Fast Universal PCR
Master Mix. All aforementioned PCR mixture and geno-
typing assay reagents were from Life Technologies Cor-
poration (Carlsbad, CA, USA). The real-time PCR
analysis was conducted using the Applied Biosystems
7500 Fast Real-Time PCR System (Life Technologies
Corp.).
Statistical analyses
Values were expressed as mean ± standard deviation
(SD). Differences between groups were identified using
the Mann-Whitney U tests and Pearson’s chi-squared
tests. The Spearman’s rank correlation coefficient was
calculated to reveal any association of esRAGE BALF
levels with esRAGE serum levels, lung function parame-
ters, and differential cell counts in the BALF in patients
with IPF. We used receiver operating characteristic
(ROC) curve analysis to find the optimal value of serum
and BALF esRAGE for predicting 5-year survival in pa-
tients with IPF. Survival was calculated with the Kaplan-
Meier approach and the log-rank test. The Cox propor-
tional hazards analysis was used to identify significant
predictors of IPF prognosis. All p-values < 0.05 were
considered significant. All data analyses were performed
using JMP statistical software version 14.1.0 (SAS Insti-
tute Inc., Cary, NC, USA).
Results
Subject characteristics
Total study population baseline characteristics are
shown in Table 1. Patients with IPF in both the serum
and BALF analysis groups were significantly older, had
higher pack-year smoking histories, and lower forced
vital capacity (FVC) than the healthy controls. There
were no significant differences in baseline characteristics
between the IPF patient serum and BALF groups. Diffu-
sion capacity for carbon monoxide (DLco) was measured
in 73 of 79 IPF patients with serum sample and 55 of 57
patients with BALF sample, respectively; this was not
correlated with age and smoking history in these pa-
tients (data not shown).
Baseline concentrations of esRAGE in blood and BALF
Serum levels of esRAGE in patients with IPF were sig-
nificantly lower than those in healthy controls (162.0 ±
102.4 ng/ml and 200.7 ± 107.3 ng/ml, respectively, p =
0.009, Fig. 1). However, there was no correlation of
esRAGE levels in the serum with lung function parame-
ters (data not shown).
Table 1 Subject baseline characteristics
Controls Patients with IPF
Serum BALF
Subjects, n 90 79 57
Age, years 53.8 ± 3.6 67.4 ± 8.8* 66.5 ± 8.8*
Sex, Male/Female 77/13 70/9 53/4
Smoking history, pack-years 16.8 ± 18.3 39.4 ± 28.5* 38.3 ± 25.0*
FVC, % predicted 109.3 ± 16.2 78.7 ± 18.2* 78.7 ± 19.2*
DLco, % predicteda – 50.2 ± 16.3 51.2 ± 16.1
BALF total cell, × 104/ml – – 21.9 ± 16.0
BALF macrophage, % – – 83.4 ± 11.4
BALF lymphocyte, % – – 11.4 ± 10.3
BALF neutrophil, % – – 3.3 ± 3.3
BALF eosinophil, % – – 1.9 ± 2.6
*vs. Control, p < 0.05 Mann-Whitney U-test
aDLco was measured in 73 of 79 IPF patients with serum sample and 55 of 57
patients with BALF sample, respectively
Values are mean ± SD unless stated otherwise
BALF bronchoalveolar lavage fluid, DLco diffusing capacity for carbon
monoxide, IPF idiopathic pulmonary fibrosis, FVC forced vital capacity
Fig. 1 Serum levels of esRAGE in patients with IPF and control subjectsThe
serum levels of endogenous secretory receptor for advanced glycation end
products (esRAGE) in patients with idiopathic pulmonary fibrosis (IPF) were
significantly lower than those in controls (162.0 ± 102.4 ng/ml and 200.7 ±
107.3 ng/ml, p=0.009, respectively). Key: boxes represent the 25th to 75th
percentiles; solid lines within the boxes show the median values; whiskers
are the 10th and 90th percentiles; and the small circles represent outliers *
p<0.05 (Mann-Whitney U-test) SD, standard deviation
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The BALF levels of esRAGE were 219.7 ± 202.7 ng/ml,
and positively associated with serum levels of esRAGE in
patients with IPF (rs = 0.317, p = 0.016; Fig. 2). The BALF
levels of esRAGE were significantly correlated with DLco
(rs = 0.406, p = 0.002; Table 2), but not with FVC and
differential cell counts in the BALF.
In this study, the baseline characteristics of age and
smoking history were not matched in patients with IPF
and control subjects, and therefore we evaluated the asso-
ciation of esRAGE levels in the serum and BALF with
these characteristics. There was no significant correlation
of esRAGE levels with age and smoking history in patients
with IPF (data not shown).
Furthermore, there was no significant difference in the
blood and BALF esRAGE levels between patients with or
without the minor allele of the RAGE gene polymorphisms
(rs1800624 and rs1800625) (Additional file 1: Table S1).
Prognostic value of esRAGE in blood and BALF
In patients with IPF, the median observation period was
42.2 months. The optimal cut-off levels for predicting 5-
year survival rates were 95 ng/ml in the serum analysis
group and 125 ng/ml in the BALF analysis group, as de-
termined by the ROC curves with area under the curve
(AUC) values of 0.716 and 0.717, respectively. The
Kaplan-Meier method and log-rank test showed that the
survival rates were significantly lower in patients with
lower levels of esRAGE in both the serum and BALF
Fig. 2 Association between the levels of esRAGE in serum and BALFThe serum levels of endogenous secretory receptor for advanced glycation
end products (esRAGE) were significantly correlated with bronchoalveolar lavage fluid (BALF) levels of esRAGE in patients with idiopathic
pulmonary fibrosis (IPF). * p < 0.05 (Spearman’s rank correlation coefficient)
Table 2 Association of BALF esRAGE levels with pulmonary
function parameters and differential cell counts in BALF (n = 57)
Variables rs P-value
Pulmonary function parameters
FVC, % predicted −0.025 0.853
DLco, % predicteda 0.406 0.002*
Differential cell counts in BALF
Total cell, × 104/ml −0.002 0.990
Macrophage, % 0.060 0.667
Macrophage, × 104/ml 0.016 0.907
Lymphocyte, % 0.125 0.369
Lymphocyte, × 104/ml 0.160 0.247
Neutrophil, % −0.049 0.727
Neutrophil, × 104/ml − 0.022 0.877
Eosinophil, % −0.117 0.400
Eosinophil, × 104/ml −0.063 0.650
* p < 0.05 Spearman’s rank correlation coefficient
aDLco was measured in 55 of 57 patients with IPF
esRAGE endogenous secretory receptor for advanced glycation end products,
BALF bronchoalveolar lavage fluid, DLco diffusing capacity for carbon
monoxide, FVC forced vital capacity
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analysis groups (p = 0.011 and p = 0.003, respectively;
Fig. 3). Univariate and multivariate Cox proportional
hazards analysis revealed that lower levels of esRAGE
were significantly correlated with poorer prognoses in
patients with IPF, in both the serum and BALF analysis
groups (Table 3).
Discussion
This study demonstrated that serum esRAGE levels in
IPF patients were significantly lower than those in
healthy controls and that lower levels of serum esRAGE
were associated with a poorer prognosis in IPF patients.
Remarkably, decreased levels of BALF esRAGE were
associated not only with decreased levels of serum
esRAGE but also with lower DLco and poorer prognosis.
These data could suggest that decreased serum levels of
esRAGE may be associated with a pro-inflammatory
condition of the lungs, which in turn decrease the levels
of esRAGE in the BALF and result in a poor prognosis.
We found that lower levels of esRAGE in blood and
BALF were independently associated with a poor prog-
nosis in patients with IPF. RAGE-ligands such as
HMGB1 and S100 proteins have been associated with
the progression of IPF. In earlier reports, it has been
shown that BALF and serum levels of HMGB1 are ele-
vated in patients with IPF and that elevated serum
Fig. 3 Five-year survival in patients with IPF based on the levels of esRAGE in serum and BALF. Decreased levels of endogenous secretory
receptor for advanced glycation end products (esRAGE) both in (a) serum and (b) bronchoalveolar lavage fluid (BALF) were significantly
associated with poorer survival in patients with idiopathic pulmonary fibrosis (IPF)
Table 3 Predicting value for 5-year mortality in IPF patients assessed by Cox proportional hazards model
Variables Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Serum (n = 79)
Age, years 0.99 0.95–1.04 0.680 – – –
Sex, Male/Female 1.16 0.27–4.98 0.648 – – –
Smoking history, pack-years 1.00 0.98–1.01 0.825 – – –
FVC, % predicted 0.94 0.91–0.98 < 0.001* 0.94 0.91–0.98 0.002*
Serum esRAGE, ng/ml 0.99 0.98–0.99 0.019* 0.99 0.98–0.99 0.028*
BALF (n = 57)
Age, years 1.02 0.97–1.08 0.474 – – –
Sex, Male/Female 0.94 0.12–7.09 0.953 – – –
Smoking history, pack-years 0.99 0.97–1.01 0.330 – – –
FVC, % predicted 0.96 0.93–0.99 0.009* 0.96 0.92–0.99 0.020*
BALF esRAGE, ng/ml 0.99 0.99–0.99 0.009* 0.99 0.98–0.99 0.041*
* p < 0.05 Cox proportional hazards model
esRAGE endogenous secretory receptor for advanced glycation end products, BALF bronchoalveolar lavage fluid, CI confidence interval, IPF idiopathic pulmonary
fibrosis, HR hazard ratio, FVC forced vital capacity
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HMGB1 levels are associated with acute deterioration
and poor prognoses for IPF [25, 26]. Additionally, Xia
et al. reported that the expression of the S100 protein
A4 (S100A4) is increased in mesenchymal progenitor
cells in patients with IPF, and increased S100A4 expres-
sion is associated with aberrant lung fibrosis in a
bleomycin-induced mouse model [27]. Furthermore,
esRAGE can act as a decoy receptor for RAGE ligands
and inhibit the RAGE/ligand interaction, which may be
associated with the IPF disease process [13–15, 28].
Therefore, the present results extend the previous prote-
omic study observations of decreased esRAGE expres-
sion in the lungs of patients with IPF [9], and indicate
that decreased esRAGE may play a role in the progres-
sion of IPF.
The total pool of circulating soluble RAGE (sRAGE)
consists of esRAGE and the ectodomain cell-surface
RAGE released by metalloproteinases, such as matrix
metalloproteinase 9 and a disintegrin and metallopro-
tease 10 [29]. In patients with COPD, sRAGE is down-
regulated in lung tissue, while esRAGE is not, and re-
duced circulatory sRAGE is associated with the decline
of lung function, while esRAGE is not [9, 30, 31]. How-
ever, this study showed that lower levels of circulatory
sRAGE were associated with poor survival in patients
with IPF, which was in line with the results of previous
studies [8, 32], and we confirmed the association of the
lung and circulatory esRAGE levels with decreased lung
function and poor prognoses. These observations indi-
cate that sRAGE and esRAGE might play different roles
in the pathophysiology of lung diseases. However, the
present results support the hypothesis that the RAGE/
ligand interaction is related to the pathophysiology of
IPF, but further investigation is warranted to elucidate
causal relationships.
Serum levels of esRAGE were significantly reduced in
patients with IPF compared to control subjects. Add-
itionally, there was a significant positive correlation be-
tween serum and BALF esRAGE concentrations. These
results are in line with those of the previous study eluci-
dating decreased esRAGE expression in the lungs in pa-
tients with IPF [9], but its mechanism is still unknown.
A possible explanation is that reduced esRAGE levels in
IPF could result from lung parenchymal damage, be-
cause this study showed that decreased levels of esRAGE
in BALF were related to reduced DLco, which was a sen-
sitive indicator of the underlying parenchymal pathology
[33–35]. Additionally, although inflammatory cells in the
lungs are a potential source of esRAGE [18, 19], there
was no correlation between esRAGE levels and differen-
tial cell counts in the BALF in this study. Another pos-
sible mechanism could be that increased RAGE/ligand
interaction in the IPF lung may diminish esRAGE in the
circulation [36]. Yet another possibility is that RAGE
gene polymorphisms, which modulate the expression of
esRAGE, could cause the altered levels of esRAGE in
IPF. In order to test this hypothesis, we investigated the
association of esRAGE concentrations with two RAGE
gene polymorphisms that influence promoter activity
(rs1800624 and rs1800625), but there was no significant
correlation [20]. Further investigations are needed to
elucidate the association between the esRAGE regulatory
mechanism and lung fibrosis.
The present study had limitations. It was conducted in
a single institution; therefore, the sample size was rela-
tively small, especially with respect to procurement of
BALF samples from IPF patients. Additionally, serum
levels of esRAGE were significantly lower in patients
with IPF than in healthy controls; however, the mean
age of IPF patients was around 10 years more than that
of healthy controls; further, more smokers were present
among patients with IPF than controls. Although
esRAGE levels in the serum and BALF were not signifi-
cantly correlated with age and smoking history in this
cohort (data not shown), this could have altered the re-
sults. Other studies to confirm the esRAGE circulatory
prognostic cut-off level and its predictive value are
necessary.
Conclusions
In conclusion, decreased esRAGE levels in both BALF
and blood were associated with a poor prognosis in pa-
tients with IPF. In particular, serum levels of esRAGE
may be a potential prognostic marker reflecting dysregu-
lated RAGE/ligand interactions in the lungs, indicated
by lower BALF levels of esRAGE. Finally, further studies
are warranted to investigate the role of the RAGE/ligand
interaction effect on the progression of IPF.
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